Introduction {#sec1}
============

IgA nephropathy (IgAN) was first described by Berger in 1968, the condition is also known as Berger's disease. IgAN is one of the most common forms of chronic glomerulonephritis, accounting for primary disease in 45%; 5--20% and 30-40% of IgAN developing in 10 and 20 years before end-stage renal failure (ESRD). However, the diagnosis, etiology, and pathogenesis of IgAN remain unclear, although serum IgA levels are high in IgAN patients. The pathological characteristics of IgAN include glomerular deposition of IgA or IgA-based immunoglobulins, glomerular mesangial cell proliferation, and extracellular matrix accumulation. During IgAN onset and progression, removal of glycosylated IgA1 from blood triggers the expression of glycan-specific IgG and IgA autoantibodies, stimulates antigen--antibody reactions, causes immune complexes to be deposited in the kidney, and induces nephritis \[[@B1]\]. Most studies suggest that IgAN may be a systemic autoimmune disease whose pathogenesis is closely linked to humoral immunity \[[@B2]\]. The B-cell receptor (BCR), a surface membrane immunoglobulin, is an important component of the B-lymphocyte recognition antigen, and exhibits antigen-binding specificity. Stimulation by a specific antigen changes the selective distribution of the BCR spectrum, which often indicates clonal B-cell proliferation and functional changes in the corresponding B cells \[[@B3],[@B4]\]. We performed multiplex PCR and high-throughput sequencing to determine BCR expression in renal biopsy tissue and the peripheral blood of patients and the peripheral blood of healthy controls (HCs). We obtained BCR *CDR3* gene sequences and subjected them to bioinformatics analysis. We combined this information with clinical data and the features of disease in both renal tissue and peripheral blood. We explored BCR heavy-chain repertoire diversity in terms of the complementarity-determining region 3 (CDR3) sequences. We sought to find diagnostic markers of IgAN non-invasiveness and markers facilitating early diagnosis, detection, and treatment.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

Fifteen IgAN patients aged 15--52 years were diagnosed, as either in- or out-patients, at the China-Japan Friendship Hospital ([Table 1](#T1){ref-type="table"}). Their clinical manifestations and immune pathologies were recorded, and all underwent standard renal biopsies to diagnose IgAN. No patient had a serious heart disease or any disease of the lung, liver, kidney, or other important organ. We enrolled 17 healthy volunteers matching with the patients in terms of gender and age. [Table 2](#T3){ref-type="table"} lists the clinical data of the 15 patients. The selection criteria for HCs were: (1) age and gender matched; (2) no apparent self-perceived discomfort and abnormality in the follow-up health checks; (3) no biological relationship with each other; (4) no medical history of autoimmune disorders, cancers, infectious diseases, liver diseases, allergy, and diabetes; and (5) no family history of autoimmune diseases.

###### Fifteen patients with IgAN tissue and peripheral blood and 17 cases of HCs peripheral blood of BCR heavy chain

  ID     Type     Raw reads (bp)   Used reads (bp)   Total CDR3   Unique CDR3   Shannon   Top1    Aver_len (bp)   HEC_rate (0.1)
  ------ -------- ---------------- ----------------- ------------ ------------- --------- ------- --------------- ----------------
  1      PBMC     6197670          4981846           3770878      64424         10.42     3.24    13.52           0.0028
  1      Tissue   6994896          5665933           4225678      38569         8.46      16.94   13.93           0.0028
  2      PBMC     6661422          5401001           3730337      250882        14.00     2.13    13.77           0.00035
  2      Tissue   5882260          4844849           3651246      38297         9.64      3.56    14.08           0.0044
  3      PBMC     5975953          4847723           3462896      172685        13.85     1.36    13.82           0.00054
  3      Tissue   7038299          5615897           4129514      41979         9.77      6.19    14.04           0.0046
  5      PBMC     8986796          8366049           7164395      112378        11.90     1.58    13.76           0.0015
  5      Tissue   10288726         9451829           8379340      33561         8.65      4.11    13.68           0.0055
  7      PBMC     10088389         9318450           7968854      188499        12.53     2.91    13.44           0.00062
  7      Tissue   8731756          8018680           6980292      54094         10.25     3.42    13.70           0.0028
  10     PBMC     8988276          8344537           7177895      134124        10.08     7.02    14.26           0.00061
  10     Tissue   8347783          7734317           6712263      44847         9.96      5.08    13.67           0.0037
  16     PBMC     7418635          5830378           4362275      50515         11.20     3.71    13.73           0.0026
  16     Tissue   7634461          6208034           4859600      33122         8.83      3.94    14.11           0.0052
  17     PBMC     5492068          4370657           3294824      41114         11.13     3.26    13.75           0.0029
  17     Tissue   7048329          5734522           4438939      29319         8.24      7.82    13.16           0.0033
  19     PBMC     6176691          5032944           3519990      111090        12.62     2.68    13.67           0.00089
  19     Tissue   6897621          5461962           4202091      31045         8.65      5.89    13.41           0.0042
  24     PBMC     5332917          4372554           3186186      100055        11.18     6.35    13.52           0.0013
  24     Tissue   4974765          4144479           3186193      27876         8.02      8.15    14.35           0.0041
  27     PBMC     5942925          4812419           3630193      45638         11.46     1.08    13.94           0.0032
  27     Tissue   5856264          4693461           3419259      22136         7.38      10.56   14.01           0.0054
  28     PBMC     5985358          4985209           3483879      195563        14.06     2.53    13.96           0.00032
  28     Tissue   5592825          4442886           3463912      15950         6.19      18.26   14.33           0.0050
  34     PBMC     5470444          4544772           3317802      117799        13.29     0.88    13.89           0.00091
  34     Tissue   5888465          4726427           3719951      23161         7.37      9.12    13.73           0.0043
  35     PBMC     5427527          4505080           3434118      47153         10.28     4.06    13.39           0.0039
  35     Tissue   6550555          5279955           4061130      17446         7.16      6.72    13.87           0.0060
  40     PBMC     5892200          4788514           3475220      55378         9.58      7.06    13.76           0.0025
  40     Tissue   5833090          4635760           3407858      11767         4.98      28.72   13.73           0.0048
  HC1    PBMC     11745589         10289027          9395964      87999         10.55     4.60    14.25           0.0018
  HC2    PBMC     10081053         8057309           6180775      65866         10.93     4.10    14.59           0.0016
  HC3    PBMC     7602175          6350154           4941667      92726         12.44     3.19    14.49           0.0015
  HC4    PBMC     5850348          4759624           3440571      54575         12.13     1.22    13.33           0.0022
  HC5    PBMC     12463042         10929066          9758191      142207        13.68     0.82    15.08           0.00076
  HC6    PBMC     8503463          7540962           6532996      199646        13.96     0.83    15.08           0.00062
  HC7    PBMC     8694452          7662936           6897677      101015        11.73     3.32    14.13           0.0016
  HC8    PBMC     8329333          7360870           6575230      116481        12.11     2.41    14.49           0.0010
  HC9    PBMC     8729682          7765847           6903670      93028         11.16     2.14    15.91           0.0020
  HC10   PBMC     8017954          7096730           6032853      300859        15.12     0.95    14.76           0.00022
  HC11   PBMC     7412442          6582725           5571827      308079        14.40     1.25    14.73           0.00021
  HC12   PBMC     7535727          6586088           6086925      70024         11.08     2.62    15.17           0.0018
  HC13   PBMC     8313829          7395497           6854417      86855         11.64     2.79    15.11           0.0015
  HC14   PBMC     7942305          7029063           6469675      72077         11.30     1.78    15.12           0.0020
  HC15   PBMC     9074623          7871457           7151031      225242        15.21     0.66    15.20           0.00018
  HC16   PBMC     7509272          6622047           6029444      167743        14.01     0.92    14.93           0.00052
  HC17   PBMC     8209623          7254345           6452053      372693        16.26     1.33    14.43           0.000060

ID, sample number; PBMC, peripheral blood mononuclear cell; Type, sample types; Raw reads, the sequencing of the original data; Used reads, after filtering is used for analysis of the number of high quality reads; Total CDR3, detect all CDR3 containing the correct reading frame number; Unique CDR3, remove duplicate CDR3 clone number; Shannon Index, H (x) = −sum \[P (x) log2 (P (x))\], in which P (x) on behalf of cloning frequency, H value, the greater the diversity, the better; Top1, the highest proportion in total clone; Aver_len, the average length of CDR3; HEC_rate, highly amplified clones in the proportion of all the clones.

###### Clinical data of 15 patients with IgAN of China-Japan friendship hospital

  ID   gender   Age (years)   Lee's pathology hierarchical   CR (umol/l)   Urea (mmol/l)   eGFR (ml/min/1.73m^2^)   24-h UprV (g)   UOsm (mOsm/kg)
  ---- -------- ------------- ------------------------------ ------------- --------------- ------------------------ --------------- ----------------
  17   Female   29            I                              58            4               119                      7.81            964
  35   Male     15            I                              152           12.86           58                       6.3             772
  24   Female   25            II                             ---           ---             ---                      4.8             ---
  1    Male     27            III                            212           6.84            37.3                     2.63            446
  3    Female   29            III                            132           8.6             60                       ---             574
  5    Male     52            III                            123           6.87            56                       3.5             637
  10   Female   31            III                            64.2          5.33            101                      1.44            983
  40   Female   30            III                            54            5.77            110                      1.5             770
  2    Male     31            IV                             108           3.94            78                       5.1             355
  7    Male     21            IV                             117           5.2             94.5                     6.57            ---
  16   Female   43            IV                             64            3.39            102                      1.96            ---
  19   Male     51            IV                             101           6.43            65.9                     1.06            700
  27   Male     42            IV                             124           5.98            60                       2.1             720
  34   Male     30            IV                             79            8.69            132                      1.34            900
  28   Male     38            V                              97            6.29            96.65                    3.04            694

We obtained kidney tissue and peripheral blood samples using standard procedures. We performed renal biopsies on the 15 IgAN patients and also took peripheral blood samples; we collected blood samples only from the 17 healthy volunteers. Renal biopsy tissue was examined microscopically, placed into RNAlater (QIAGEN) collection tubes, and stored at −80°C. Ficoll-Paque PREMIUM (GE Healthcare) was used to purify peripheral blood mononuclear cells (PBMCs) from peripheral blood samples. These were mixed with TRIzol (Invitrogen) in collection tubes and stored at −80°C.

Preparation of immune system libraries {#sec2-2}
--------------------------------------

The TRIzol method was used to extract total RNA from 15 tissue samples and 32 PBMCs. We employed an Agilent 2100 platform (Agilent Technologies) to perform quality control \[[@B8]\]. After addition of DNase I, we mixed 200 ng of total RNA with 20 ng of each of six random primers, 1 μl of dNTP mixture (all 10 mM), reverse transcription-DEPC, and H~2~O to final volumes of 12 μl. All tubes were incubated at 65°C for 5 min and then placed on ice. After centrifugation, each pellet was incubated with 4 μl of 5× first-strand buffer, 1 μl DTT (0.1 M), and 1 μl RNaseOUT (40 units/μl) (SuperScript® Retrovirus Kit, Invitrogen). After mixing, all tubes were placed at room temperature for 2 min. Next, 1 μl SuperScript™ II RT (Invitrogen) was added, the solutions were mixed, and reverse transcription proceeded (after pretreatment at 70°C for 15 min) for 50 min at 42°C. All samples were then subjected to PCR amplification (Multiplex PCR Kit, QIAGEN); the β forward primer was Vβ (0.2 μΜ), and the β reverse primer was Jβ (both 0.2 μΜ). The PCR protocol was 95°C for 15 min, followed by 30 cycles at 94°C for 30 s, 60°C for 90 s, 72°C for 30 s, 72°C for 5 min, and a drop to 12°C. A QIAquick Gel Extraction (QIAGEN) Kit was used to purify amplification products of 100--200 bp.

PCR amplification was performed using 12 V-area specific primers and 1 J-area degenerate primer. We avoided primer dimers, sought to reduce amplification, and aimed to maximally cover the BCR heavy-chain gene family and J genes and the V family area \[[@B5]\].

After purification, the PCR amplification products were used to prepare DNA sequencing libraries (Illumina). Library quality was confirmed, and the libraries were sequenced using an Illumina Hiseq2500 sequencing platform running PE100 chemistry.

Bioinformatics {#sec2-3}
--------------

The IMGT website (<http://www.imgt.org/>), which contains information on B-cell V genes and J and D gene sequences, was used to build a reference sequence dataset. The website states that the 2th V genes encode cysteines at the 3′ ends, and that BCR heavy-chain CDR3 proteins have phenylalanines at the 5′ ends of the regional start and stop sequences \[[@B6]\].

We used IMonitor software \[[@B7]\] to process the original reads. This software runs in the R statistical language (version 2.15.3). We used the package ggplot2 (version 0.9.3.1) for data analysis and diagramming. *P*-values were calculated with the aid of the *t* test. A single asterisk (\*) indicated *P*≤0.05; two asterisks (\*\*) *P*≤0.01; and three asterisks (\*\*\*) *P*≤0.001. Values of *P*≤0.05 were deemed to indicate significant differences.

We calculated the Shannon entropies of highly expressed clones and the highest frequencies of library immune system diversities. Shannon entropy is commonly used to evaluate the diversity of immune system libraries. The index considers not only CDR3 types, but also their ratios. The more uniform the CDR3 distribution is, the highter is the Shannon diversity index. A cloning frequency \> 0.1% was defined as high; all such clones were identified by their the highly expanded clonal (HEC) ratios.

At the same time, our team participated as a participant in the work of Huang's team. Currently, Huang et al.'s article has been published \[[@B9]\], although we are concerned about the different immune expression of IgAN patients, the high-throughput detection techniques we use are identical. The publication of Huang et al. \[[@B9]\]also gives us a strong support for this article. I think that the publication of Huang et al. \[[@B9]\] and our work will open a new chapter in the study of IgAN.

Results {#sec3}
=======

Detection of BCR heavy-chain CDR3 genes expressed in IgAN patients and HCs {#sec3-1}
--------------------------------------------------------------------------

High-throughput sequencing (using an Illumina platform) was performed on peripheral blood samples and renal tissue samples of 15 IgAN patients to obtain libraries of BCR heavy chains. Each library was filtered to obtain high-quality reads (approximately 5.70 Mb) and compared with databases containing 64.98 and 68.84 Mb of BCR CDR3 sequences (1687297 and 463169 different sequences, respectively). We sought to identify lesions of the BCR CDR3 immune repertoire in renal tissue and peripheral blood of patients. We also analyzed 17 peripheral blood samples from HCs, obtaining approximately 98.79 Mb of CDR3 BCR sequences (2016679 different sequences), to establish the CDR3 immune repertoire of healthy blood. The sequencing data are shown in [Table 1](#T1){ref-type="table"}.

Data on the peripheral blood heavy-chain CDR3 BCR immune libraries of patient \#28 and HC \#15 are shown in three dimensions in [Figure 1](#F1){ref-type="fig"}. The immune repertoire diversity of the patient was lower than that of the healthy volunteer, and some CDR3 sequences were more frequent in the patient.

![Peripheral blood BCR heavy-chain CDR3 immune library data of an IgAN patient and a healthy volunteer\
(**A**) Data from IgAN patient \#28; (**B**) data from healthy volunteer \#15.](bsr-39-bsr20190482-g1){#F1}

Diversity of the BCR heavy-chain immune repertoire in peripheral blood {#sec3-2}
----------------------------------------------------------------------

The Shannon diversity indices for the peripheral blood BCR heavy-chain immune repertoires of IgAN patients and HCs were 11.84 ± 1.49 and 12.81 ± 1.76, respectively; these values did not differ significantly ([Figure 2](#F2){ref-type="fig"}A). There was thus no significant difference in the peripheral blood CDR3 distribution of BCR heavy-chain immune repertoires between HCs and IgAN patients. We then compared the proportion of highly expressed clones with that of all clones. The HEC ratios of the IgAN patients and controls were 0.0017 ± 0.0012 and 0.0012 ± 0.00074, respectively, which were not significantly different ([Figure 2](#F2){ref-type="fig"}B). Both groups had few highly amplified clones, and there was no significant difference in the extent of amplification. In addition, the *Top1* clone was the most highly expressed in both HCs and IgAN patients. The clonal frequency in IgAN patients (3.32 ± 2.04) was higher than that in HCs (2.05 ±1.22) ([Figure 2](#F2){ref-type="fig"}C).

![Diversity of BCR heavy-chain groups in the peripheral blood of IgAN patients and HCs\
(**A**) Shannon diversity index (*P=0.10*); (**B**) HEC ratio (*P=0.17*); (**C**) Top1 clone (*P=0.047*).](bsr-39-bsr20190482-g2){#F2}

Distribution of the V/J gene family of BCR heavy chains in peripheral blood {#sec3-3}
---------------------------------------------------------------------------

The distributions of specific V and J subtypes in the peripheral blood of IgAN patients and HCs were evaluated by calculating the proportions of sequences in the V and J gene families.

As shown in [Figure 3](#F3){ref-type="fig"}, 48 V subtypes of 7 V gene families and 6 J genes were expressed in the peripheral blood BCR heavy-chain libraries of both IgAN patients and HCs. The frequencies of V1, V5, V6, V7 and J4, J5, and J6 were higher than others. The two groups did not differ significantly in terms of either V or J gene distribution ([Figure 3](#F3){ref-type="fig"}A,B).

![Distribution of V and J gene subtypes among peripheral blood BCR heavy-chains of HCs and IgAN patients\
(**A**) V gene distribution (*P=0.93*); (**B**) J gene distribution (*P=1.00*).](bsr-39-bsr20190482-g3){#F3}

BCR regional length distribution in CDR3 heavy chains of peripheral blood {#sec3-4}
-------------------------------------------------------------------------

The literature suggests that the length of the CDR3 region affects the three-dimensional structure of the CDR3 ring, thus influencing antigen-binding specificity. Therefore, we calculated the CDR3 lengths of the IgH sequences of BCR heavy chains of IgAN patients and HCs. The average CDR3 length in IgAN patients was 13.74 ± 0.22 nt, significantly shorter than that of HCs (14.76 ± 0.57 nt) ([Figure 4](#F4){ref-type="fig"}A).

![CDR3 lengths and BCR heavy-chain variant frequencies in the peripheral blood of IgAN patients and HCs\
(**A**) The peripheral blood BCR heavy-chain repertoire in terms of CDR3 length in HCs and IgAN patients (*P=1.02e-06*); (**B**) the peripheral blood IgAN variant frequencies of genes encoding BCR heavy chains in IgAN patients and HCs. Abbreviations: NB, peripheral blood of IgAN patients; Nor, peripheral blood of HCs; NT, tissue of IgAN patients.](bsr-39-bsr20190482-g4){#F4}

Frequency of BCR heavy-chain variants in tissue and peripheral blood {#sec3-5}
--------------------------------------------------------------------

BCR formation should precede gene rearrangement in somatic cells. During an immune response, mature B cells stimulated by antigens during differentiation and development accumulate high levels of somatic variants, increasing BCR diversity. Analysis of variants in genes encoding BCR heavy chains is important in terms of infection, aging, and the development of autoimmune diseases and tumors. We found ([Figure 4](#F4){ref-type="fig"}B) that tissues from patients had an average of 10.64 ± 0.37 IgH variants, significantly more than found in the peripheral blood of both patients (7.71 ± 1.27, *P=1.83e-07*) and controls (6.70 ± 0.88, *P=4.81e-14*). Also, the average number of IgH variants in the peripheral blood of patients was higher than that in controls ([Figure 4](#F4){ref-type="fig"}B, *P=0.016*). BCR variant frequency was obviously higher in patients than controls, and was highest in renal tissue.

Comparison of BCR heavy-chain groups in tissue and peripheral blood {#sec3-6}
-------------------------------------------------------------------

A correlation study showed that consistency between tissue and peripheral blood data indirectly reflected disease characteristics. We normalized the numbers of BCR heavy-chain CDR3 sequences in patient tissue and peripheral blood samples, selected 10000 sequences, and then calculated Pearson correlation coefficients of patient tissue and peripheral blood libraries with control libraries. Fewer renal tissue BCR heavy chains (and thus CDR3s) were expressed in both tissues and peripheral blood of IgAN patients (Pearson correlation coefficients \< 0.2 for all patients).

Characteristics of tissue and peripheral blood BCR heavy-chain libraries in clonal terms {#sec3-7}
----------------------------------------------------------------------------------------

To further explore changes in the renal and peripheral blood BCR heavy-chain repertoires of IgAN patients, we identified renal BCR heavy chains that 'shared' CDR3 sequences in 15 IgAN patients and analyzed their expression levels in the corresponding peripheral blood samples. The results showed that a total of 28268 BCR CDR3 sequences were shared by different IgAN patient tissue B cells. Among them, 14, 13, 12, 10, 9, and 8 patients had 'common' sequences of 1, 3, 55, 41, 57, 58, and 118 species. We found that at least 13 patients had the 'ALYFHNSAY', 'ARWGPMYYYMDV', 'ARDQGALNA', and 'ARVDNPADF' sequences; we calculated their frequency distributions in tissues and their average frequencies in peripheral blood of the 15 patients mentioned above and of all patients. We found ([Table 3](#T2){ref-type="table"}) that the 'common' four CDR3 sequences were present at high frequencies in peripheral blood. In addition, the 'shared' CDR3 sequences of patients differed considerably in both abundance and length. This may be associated with antigenic stimulation during disease progression and development of the immune response.

###### IgAN disease characteristics in terms of the four types of BCR heavy-chain CDR3 sequences

  CDR3           Freq SN   Average frequency in peripheral blood                                                                                                       
  -------------- --------- --------------------------------------- ------- ------- ------- ------- ------- ------- ------- --- ------- ------- ------- ------- ------- -------
  ALYFHNSAY      3687      24663                                   2       94793   24      23871   4249    801     27423   0   18      3784    29293   53845   2       4399
  ARWGPMYYYMDV   1321      713                                     2       71095   97034   0       4970    29382   27423   0   41207   1267    29293   12      86739   10058
  ARDQGALNA      28268     201                                     31433   3       86      0       50827   476     110     0   4       15795   6       2       2       5238
  ARVDNPADF      2542      49327                                   31433   23698   3       0       5704    29382   27423   0   10      3248    4       26923   86739   4971

Discussion {#sec4}
==========

IgAN is the most common primary glomerular disease; both the pathogenesis and the detailed mechanism of progression remain unclear. It is generally believed that large amounts of glycosylation-deficient IgA1 in blood trigger the development of glycan-specific IgG and IgA autoantibodies and the formation of immune complexes. These are abnormally secreted from the mucosa into the blood, ultimately being deposited in the kidney \[[@B1]\]. Thus, IgAN may be a systemic autoimmune disease; the adaptive immune response may be compromised.

Humoral immunity conferred by B cells is closely associated with the formation of specific IgG and IgA autoantibodies, which in turn maybe intimately connected to IgAN development1. The BCR is important in terms of B-cell recognition and antigen binding, thus playing a key role in the humoral immune response. Effective adaptive immunity requires a rich and diverse BCR repertoire2. Adult peripheral blood contains approximately 1--2 × 10^11^ B lymphocytes and 3--9 × 10^9^ BCR heavy-chain CDR3s3. Each B lymphocyte produces a functional BCR heavy-chain CDR3 protein. Therefore, estimation of the diversity of BCR heavy-chain CDR3 sequences allows us to define the extent of amplification of the corresponding B-cell clones. This, in turn, measures the functional status of B cells. Considering that B cell-mediated humoral immunity is closely related to the formation of IgG and IgA autoantibodies specific for polysaccharides, it may be closely related to the formation of IgAN. The reason why we did not focus on the analysis of sIgA and sIgD B cell subsets was due to our current research methodology. We studied the B cell receptor and the CDR3 sequence of the multiple PCR and NGS, which is not included in the C region of the primers. Unfortunately, there no chance for classification analysis. This article is also our team in this area of the first step in the study, we will further enhance our research methods, hope in the follow-up study, can be classified research. Maybe V-C primers can help us with the next experiment.

Previous studies indicated that the BCR was involved in somatic gene rearrangements during an immune response. The BCR undergoes somatic cell variant, thereby greatly increasing the size of the BCR library. We studied the peripheral blood and renal tissues of 15 IgAN patients and the peripheral blood of 15 healthy volunteers in terms of the BCR heavy-chain immune repertoire. We compared the BCR heavy-chain variant frequencies between the groups and found that this was significantly higher in renal tissue than the peripheral blood of both patients and controls. Also, the IgH variant frequency was significantly higher in the peripheral blood of patients than that of controls. In addition, the BCR of patients exhibited a higher variant frequency, suggesting that antigen-specific IgAN reflected sustained activation of the adaptive immune system B-cell differentiation to form proliferating plasma cells and relatively high-frequency variants. The latter may be closely related to the instigation and progression of IgAN. Because of the pathogenesis of IgAN, the BCR spectrum undergoes a selective distribution due to specific antigen stimulation, often leading to clonal proliferation and functional changes in the corresponding B cells. Based on this, we are only tentatively trying to find specific disease markers in B cells that can be seen due to changes induced by specific antigen stimuli. And the primary purpose is to use this as a noninvasive diagnostic marker for IgAN.

To explore the association between the immune responses of renal tissue and peripheral blood, and the progression of IgAN, 15 patients were compared in terms of peripheral blood and renal tissue BCR heavy chains. All Pearson correlation coefficients were \<0.2; only weak correlations were thus evident between renal tissue and peripheral blood samples. However, further analysis showed that at least 13 patients had the 'ALYFHNSAY', 'ARWGPMYYYMDV', 'ARDQGALNA', and 'ARVDNPADF' sequences, and also four other types of CDR3 clones. The last were present at high frequencies in the peripheral blood of the 15 patients, but not that of the 15 controls. These four CDR3 clones may be characteristic of IgAN, being present at high frequencies in both renal tissue and peripheral blood. They may serve as noninvasive diagnostic markers of IgAN, but further research and clinical verification are required. Before completing the present study, we did not know that the BCR variants were not synchronized in the tissue and in the peripheral blood. According to basic immunology, BCR variants come from somatic high frequency variants in antibody affinity maturation stages, so we have reason to speculate that BCR variants in tissues may be caused by stimulation of renal tissue. Peripheral blood and tissue of the different reasons may be more complex, we want to examine whether the peripheral blood can reflect the characteristics of the lesion and so on. Because kidney tissue is the last point of concern, therefore, should be the kidney tissue variant point as a reference, we look forward to finding the same peripheral blood and kidney tissue mutant phenotype. We also continue to expand the sample size on the basis of existing research, and then to verify the markers have been found, and in the further study, it is possible to find new and more reliable and more accurate markers.

Conclusions {#sec5}
===========

We sequenced the immune repertoires of renal tissue and peripheral blood of IgAN patients and healthy volunteers. We constructed BCR heavy-chain libraries and found that the heavy-chain variant frequency was significantly higher in patients than in controls. IgAN was characterized by four CDR3 clones that may serve as noninvasive markers of disease. We also discovered four high-variant CDR3 sites. We plan to conduct animal experiments to explore the effects of variants at these four sites and their roles in IgAN.
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